The Chinese biotech company received regulatory clearance for its BBM-H901 treatment, marking the country's inaugural gene therapy for the bleeding disorder.

Belief BioMed ("BBM") today announced that BBM-H901 (generic name: Dalnacogene Ponparvovec Injection), has been officially approved by the Pharmaceutical Administration Bureau of Macao Special ...

The researchers say that, to their knowledge, this is the first demonstration of programmable, site-specific integration of a large DNA payload into T cells in vivo.

Crossing American chestnuts with naturally blight-resistant Chinese chestnuts results in hybrids with substantial blight ...

Foundational research led by co-founder Justin Eyquem, Ph.D., underpins Azalea's proprietary in vivo CAR T platform -- Peer-reviewed publication demonstrates stable, cell-specific transgene expression ...

New research shows epigenetic silencing may limit durability of AAV gene therapy in haemophilia by reducing long term transgene expression in liver cells.

WEST LAFAYETTE, IN, UNITED STATES, March 5, 2026 /EINPresswire.com/ -- Advancing Agricultural Excellence Through Plant ...

On February 26, 2026, Neurogene announced that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to NGN-401, its late-stage investigational AAV9 gene therapy for Rett ...

Transgene (Euronext: TNG) is a biotechnology company focused on designing and developing targeted immunotherapies for the treatment of cancer. The Company’s clinical-stage programs consist of a ...

Strasbourg, France, January 23, 2026, 8:00 a.m. CET – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, announced ...

This press release may not be distributed directly or indirectly in the United States, the United Kingdom, Canada, Australia, or Japan. Fundraising consisting of a reserved offering to international ...